Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective

The application of physiologically based pharmacokinetic (PBPK) modeling has developed rapidly within the pharmaceutical industry and is becoming an integral part of drug discovery and development. In this study, we provide a cross pharmaceutical industry position on “how PBPK modeling can be applied in industry” focusing on the strategies for application of PBPK at different stages, an associated perspective on the confidence and challenges, as well as guidance on interacting with regulatory agencies and internal best practices.

[1]  Anna M. Wu,et al.  A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn) , 2005, Annals of Biomedical Engineering.

[2]  Fahima Nekka,et al.  Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. , 2010, Journal of pharmaceutical sciences.

[3]  L. A. Fenu,et al.  The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools , 2007, Drug Metabolism and Disposition.

[4]  Dhaval K. Shah,et al.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[5]  Karen Rowland-Yeo,et al.  Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling , 2013, Clinical Pharmacokinetics.

[6]  J. Dressman,et al.  Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update , 2008, Pharmaceutical Research.

[7]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[8]  Kuresh Youdim,et al.  Application of PBPK modelling in drug discovery and development at Pfizer , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[9]  Sheila Annie Peters,et al.  Identification of Intestinal Loss of a Drug through Physiologically Based Pharmacokinetic Simulation of Plasma Concentration-Time Profiles , 2008, Clinical pharmacokinetics.

[10]  Hefei Zhang,et al.  Utility of Physiologically Based Modeling and Preclinical In Vitro/In Vivo Data to Mitigate Positive Food Effect in a BCS Class 2 Compound , 2013, AAPS PharmSciTech.

[11]  Sebastian Polak,et al.  Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.

[12]  Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , Implications for Dosing , and Labeling Recommendations , 2022 .

[13]  Erik Sjögren,et al.  In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  Patrick Poulin,et al.  Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches , 2012, The AAPS Journal.

[15]  K. Pang,et al.  Commentary: Theoretical Predictions of Flow Effects on Intestinal and Systemic Availability in Physiologically Based Pharmacokinetic Intestine Models: The Traditional Model, Segregated Flow Model, and QGut Model , 2012, Drug Metabolism and Disposition.

[16]  Yuan Chen,et al.  Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies , 2012, Biopharmaceutics & drug disposition.

[17]  Joseph P. Balthasar,et al.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  Tycho Heimbach,et al.  Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data , 2009, The AAPS Journal.

[19]  Kazuya Maeda,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.

[20]  Kiyohiko Sugano,et al.  Introduction to computational oral absorption simulation. , 2009, Expert opinion on drug metabolism & toxicology.

[21]  Jan Snoeys,et al.  From preclinical to human – prediction of oral absorption and drug–drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example , 2012, Biopharmaceutics & drug disposition.

[22]  Manfred Kansy,et al.  Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model , 2008, Drug Metabolism and Disposition.

[23]  Helen J. Lachmann,et al.  In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes , 2009, The Journal of experimental medicine.

[24]  M Rowland,et al.  Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions , 2012, Clinical pharmacology and therapeutics.

[25]  D. Stepensky,et al.  Local versus Systemic Anti-Tumour Necrosis Factor-α Effects of Adalimumab in Rheumatoid Arthritis , 2012, Clinical Pharmacokinetics.

[26]  Thierry Lavé,et al.  An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. , 2005, Journal of pharmaceutical sciences.

[27]  Michael Levin,et al.  Extended Release Oral Dosage Forms‚ÄîDevelopment,Evaluation, and Application of In Vitro/In Vivo Correlations , 2001 .

[28]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[29]  K. Johnson.  An Update. , 1984, Journal of food protection.

[30]  J. Dressman,et al.  Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. , 2011, Journal of pharmaceutical sciences.

[31]  J Brian Houston,et al.  Saturable Uptake of Lipophilic Amine Drugs into Isolated Hepatocytes: Mechanisms and Consequences for Quantitative Clearance Prediction , 2007, Drug Metabolism and Disposition.

[32]  B. Agoram,et al.  Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models , 2014, CPT: pharmacometrics & systems pharmacology.

[33]  L. Berezhkovskiy,et al.  The corrected traditional equations for calculation of hepatic clearance that account for the difference in drug ionization in extracellular and intracellular tissue water and the corresponding corrected PBPK equation. , 2011, Journal of pharmaceutical sciences.

[34]  K. Sandy Pang,et al.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[35]  T Lavé,et al.  Challenges and opportunities with modelling and simulation in drug discovery and drug development , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[36]  Sheila Annie Peters,et al.  Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Lineshape Analysis , 2008, Clinical pharmacokinetics.

[37]  Torsten Teorell,et al.  Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .

[38]  R K Jain,et al.  Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. , 1995, Cancer research.

[39]  Hannah M Jones,et al.  Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling , 2011, Clinical pharmacokinetics.

[40]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[41]  Neil Parrott,et al.  Applications of physiologically based absorption models in drug discovery and development. , 2008, Molecular pharmaceutics.

[42]  Filippos Kesisoglou,et al.  Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[43]  Janne T. Backman,et al.  Reevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant Concentrations , 2011, Drug Metabolism and Disposition.

[44]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[45]  Malcolm Rowland,et al.  PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. , 2011, Journal of pharmaceutical sciences.

[46]  S-M Huang,et al.  Regulatory Experience With Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials , 2012, Clinical pharmacology and therapeutics.

[47]  Thuy Tran,et al.  Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development , 2013, Drug Metabolism and Disposition.

[48]  Sheila Annie Peters,et al.  Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[49]  Walter Schmitt,et al.  A physiological model for the estimation of the fraction dose absorbed in humans. , 2004, Journal of medicinal chemistry.

[50]  Hugues Dolgos,et al.  Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization. , 2009, Current opinion in drug discovery & development.

[51]  Jin Y. Jin,et al.  A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer , 2013, Biopharmaceutics & drug disposition.

[52]  Elie Dolgin.  Oral solutions. , 2015, Scientific American.

[53]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[54]  Tetsuya Terasaki,et al.  Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. , 2011, Journal of pharmaceutical sciences.

[55]  Jennifer B Dressman,et al.  Designing biorelevant dissolution tests for lipid formulations: case example--lipid suspension of RZ-50. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[56]  Otto D. Payton,et al.  Implications for Clinical Practice , 1983 .

[57]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON THE EVALUATION OF THE PHARMACOKINETICS OF MEDICINAL PRODUCTS IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION , 2005 .

[58]  M Rowland,et al.  The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review , 2012, Clinical pharmacology and therapeutics.

[59]  Tycho Heimbach,et al.  Case Studies for Practical Food Effect Assessments across BCS/BDDCS Class Compounds using In Silico, In Vitro, and Preclinical In Vivo Data , 2012, The AAPS Journal.

[60]  Khaled Abduljalil,et al.  Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations , 2014, Drug Metabolism and Disposition.

[61]  Malcolm Rowland,et al.  Physiologic modeling of cyclosporin kinetics in rat and man , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[62]  Hugh A. Barton,et al.  Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.

[63]  Sheila Annie Peters,et al.  Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry , 2012 .

[64]  Michael B Bolger,et al.  In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. , 2012, Molecular pharmaceutics.

[65]  Shiew-Mei Huang,et al.  Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice , 2012, Biopharmaceutics & drug disposition.

[66]  James M. Gallo,et al.  The Pharmacokinetic/Pharmacodynamic Pipeline: Translating Anticancer Drug Pharmacology to the Clinic , 2011, The AAPS Journal.

[67]  T. Lavé,et al.  A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics , 2006, Clinical pharmacokinetics.

[68]  Guideline on the Investigation of Drug Interactions , 2010 .

[69]  Shiew-Mei Huang,et al.  The utility of modeling and simulation in drug development and regulatory review. , 2013, Journal of pharmaceutical sciences.

[70]  Hans Lennernäs,et al.  In Vivo Investigation in Pigs of Intestinal Absorption, Hepatobiliary Disposition, and Metabolism of the 5α-Reductase Inhibitor Finasteride and the Effects of Coadministered Ketoconazole , 2011, Drug Metabolism and Disposition.

[71]  Kiyohiko Sugano,et al.  Prediction of food effect by bile micelles on oral drug absorption considering free fraction in intestinal fluid. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[72]  G. Tucker,et al.  A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance , 2010, Clinical pharmacokinetics.

[73]  K Rowland-Yeo,et al.  Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development , 2013, CPT: pharmacometrics & systems pharmacology.

[74]  Tetsuya Terasaki,et al.  Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria , 2008, Pharmaceutical Research.